Date: 2014-01-24
Type of information: R&D agreement
Compound: aerosol antibody formulation
Company: Sanofi (France) MAbImprove (France)
Therapeutic area: Rare diseases
Type agreement: R&D
development
Action mechanism:
Disease: idiopathic pulmonary fibrosis
Details: * On January 24, 2014, Sanofi and MAbImprove “Laboratoire d’Excellence” (LabEx), coordinated by the Université François-Rabelais de Tours, have announced a two-year public- private partnership to develop an aerosol antibody formulation to treat patients with idiopathic pulmonary fibrosis, an orphan disease for which there are no effective treatment options. The project is focused primarily on developing an optimal formulation for antibody inhalation to the lung. The partnership will leverage the expertise of multidisciplinary teams within the Université François-Rabelais de Tours and teams from the university’s Center for the Study of Lung Diseases (CEPR), INSERM, including Dr. Nathalie Heuzé-Vourc\'h,and Sanofi R&D teams at Chilly-Mazarin/Longjumeau and Vitry-sur-Seine/Alfortville in France and at Genzyme in the United States.
MAbImprove has been ecognized as a \"Laboratory of Excellence\" by the French government within the \"Investment for the Future\" project. MAbImprove is dedicated to optimizing the development of therapeutic monoclonal antibodies.
Financial terms:
Latest news:
